1. Home
  2. HOLX vs UTHR Comparison

HOLX vs UTHR Comparison

Compare HOLX & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOLX
  • UTHR
  • Stock Information
  • Founded
  • HOLX 1985
  • UTHR 1996
  • Country
  • HOLX United States
  • UTHR United States
  • Employees
  • HOLX N/A
  • UTHR N/A
  • Industry
  • HOLX Medical Electronics
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • HOLX Health Care
  • UTHR Health Care
  • Exchange
  • HOLX Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • HOLX 12.1B
  • UTHR 14.4B
  • IPO Year
  • HOLX 1990
  • UTHR 1999
  • Fundamental
  • Price
  • HOLX $64.48
  • UTHR $290.75
  • Analyst Decision
  • HOLX Hold
  • UTHR Buy
  • Analyst Count
  • HOLX 13
  • UTHR 13
  • Target Price
  • HOLX $76.27
  • UTHR $393.08
  • AVG Volume (30 Days)
  • HOLX 3.8M
  • UTHR 693.7K
  • Earning Date
  • HOLX 07-28-2025
  • UTHR 07-30-2025
  • Dividend Yield
  • HOLX N/A
  • UTHR N/A
  • EPS Growth
  • HOLX 25.36
  • UTHR 18.86
  • EPS
  • HOLX 2.39
  • UTHR 25.10
  • Revenue
  • HOLX $4,026,500,000.00
  • UTHR $2,994,100,000.00
  • Revenue This Year
  • HOLX $2.99
  • UTHR $14.30
  • Revenue Next Year
  • HOLX $4.91
  • UTHR $6.32
  • P/E Ratio
  • HOLX $26.76
  • UTHR $11.58
  • Revenue Growth
  • HOLX 1.66
  • UTHR 19.84
  • 52 Week Low
  • HOLX $51.90
  • UTHR $266.98
  • 52 Week High
  • HOLX $84.67
  • UTHR $417.82
  • Technical
  • Relative Strength Index (RSI)
  • HOLX 60.95
  • UTHR 42.82
  • Support Level
  • HOLX $63.76
  • UTHR $282.89
  • Resistance Level
  • HOLX $65.72
  • UTHR $329.85
  • Average True Range (ATR)
  • HOLX 1.35
  • UTHR 9.17
  • MACD
  • HOLX -0.03
  • UTHR -2.82
  • Stochastic Oscillator
  • HOLX 72.07
  • UTHR 27.45

About HOLX Hologic Inc.

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: